← Human Trials & Peer-Reviewed Studies
Effects of continuous versus intermittent exercise, obesity, and gender on growth hormone secretion.
Plain-language guide to PMID 18782875 (2008): clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 18782875
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2008
- Study type
- Clinical Trial
- Authors
- Weltman A et al. (9 authors)
- DOI
- 10.1210/jc.2008-0998
What This Study Did, in Plain Language
What Was Tested
This clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The objective of the study was to examine whether intermittent and continuous exercise interventions evoke similar patterns of 24-h GH secretion and whether responses are attenuated in obese subjects or affected by gender.
Why It Was Studied
Obesity attenuates spontaneous GH secretion and the GH response to exercise.
Obese individuals often have low fitness levels, limiting their ability to complete a typical 30-min bout of continuous exercise.
Who Took Part
By PubMed's age tags, the people studied were young adults and adults, both men and women.
This was a repeated-measures design in which each subject served as their own control.
Subjects were healthy nonobese (n = 15) and obese (n = 14) young adults.
How the Study Was Run
This study was conducted at the University of Virginia General Clinical Research Center.
What Was Measured
Obese individuals often have low fitness levels, limiting their ability to complete a typical 30-min bout of continuous exercise.
PubMed files the paper under topics including Anaerobic Threshold, Body Composition, Body Mass Index, Data Interpretation, Statistical, Exercise, Half-Life and Human Growth Hormone.
What This Means in Plain Language
This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2008 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.